Nanosuspension containing progerinin and method for producing same

A nanosuspension formulation with optimized polymer and surfactant ratios stabilizes progerinin, addressing sedimentation and chemical instability issues, enhancing bioavailability and stability for effective therapeutic use.

JP2024542259AActive Publication Date: 2024-11-13PRG S&TECH INC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2024530513
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2021-12-08
Publication Date
2024-11-13
Estimated Expiration
2041-12-08

AI Technical Summary

Technical Problem

Progerinin, a drug with low water solubility, faces challenges in formulation due to rapid sedimentation and chemical instability in aqueous suspensions, leading to inconsistent dosages and difficulty in administration, which limits its therapeutic applications for progeria.

Method used

A nanosuspension formulation containing progerinin with specific ratios of hydroxypropyl methylcellulose (HPMC) or hydroxypropyl cellulose (HPC), D-α-tocopherol polyethylene glycol succinate (TPGS) or dioctyl sodium succinate (DOSS), and potassium sorbate, with an average particle size of 100 to 300 nm, produced through wet ball milling, to enhance stability and bioavailability.

Benefits of technology

The nanosuspension provides improved stability, uniform dispersibility, and enhanced bioavailability of progerinin, maintaining homogeneity for over 20 days and ensuring effective absorption even at low temperatures.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542259000001_ABST
    Figure 2024542259000001_ABST
Patent Text Reader

Abstract

The present invention relates to a nanosuspension formulation suitable for poorly soluble progerinin drugs and a method for preparing the same. Specifically, the progerinin nanosuspension according to the present invention is a vehicle composition for improving the dispersion stability of poorly soluble progerinin drugs (a), and is prepared by using hydroxypropylmethylcellulose (HPMC) (b) or hydroxypropylcellulose (HPC) (b'), TPGS (c) or dioctyl sodium succinate (DOSS) (c') and potassium sorbate (d), and subjecting the mixture to wet ball milling in a dyno mill chamber to prepare a white nanosuspension containing a progerinin drug with an average particle size of 100 to 300 nm. Such a nanosuspension has uniform dispersion of progerinin drug particles, minimized size change of drug particles even at low temperatures or in harsh environments, and excellent bioabsorption efficiency of the drug. Therefore, the nanosuspension containing progerinin according to the present invention is widely used as an oral nanosuspension formulation for confirming the therapeutic effect of premature aging.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a nanosuspension containing the poorly soluble drug progerinin and a method for producing the same. [Background technology]

[0002] Many useful drugs are hydrophobic with low solubility in aqueous media, making them difficult to formulate into suspensions in aqueous vehicles. In particular, due to such characteristics, wetting agents are often required to promote the suspension of hydrophobic drug particles in aqueous media. Surface-active wetting agents (i.e., surfactants), such as sodium lauryl sulfate, are known to at least partially increase the suspendability of hydrophobic drugs in aqueous media by reducing the interfacial tension between drug particles and the suspension vehicle, allowing the suspension vehicle to penetrate into drug aggregates and / or drug particle pores. However, apart from the beneficial drug-suspension effect, the use of surfactants in suspensions also leads to the undesirable result of solubilized and / or dissolved free drug.

[0003] Suspensions containing free drug are chemically unstable because solubilized and / or dissolved drugs are vulnerable to chemical degradation and / or interactions with other components. Yet another undesirable consequence of using a relatively high amount of surfactant to promote the suspension of low-solubility drugs is that air entrained during homogenization or shaking of such suspensions tends to remain trapped because the surfactant stabilizes air bubbles. Such trapped air changes the volume of the suspension, depending on the stirring force, stirring duration, and stirring elapsed time, making it difficult or impossible to administer a uniform dose over time.

[0004] If a drug with low water solubility is administered as a suspension, it is desirable for the suspension to exhibit slow settling to provide adequate dose uniformity. Conversely, if rapid settling occurs, as in the case of a vehicle, the suspension must be shaken before every administration to achieve dose uniformity. Other factors being equal (e.g., drug particle size, uniformity, and density), as the viscosity of a particular suspension vehicle increases, the rate of settling of drug particles decreases. Thus, it is desirable for the suspension to be appropriately viscous to inhibit or slow down the settling of drug particles. However, while such increased viscosity promotes physical stability, it also makes the suspension difficult to pour or administer.

[0005] Meanwhile, progerinin having the structure of the following chemical formula 1 shows excellent progerin expression inhibitory effects and inhibitory effects on the binding of progerin to lamin A, and is a drug having the effect of extending the survival time of an animal model in which progeria is induced, and is used as a pharmaceutical composition for preventing or treating progeria.

[0006] [ka]

[0007] The compound name of the progerinin is (7S)-(+)-8,8-Dimethyl-7-(3-phenylallyloxy)-7,8-dihydro-6H-pyrano[3,2-g]chromen-2-one (which is named "SLC-D011").

[0008] Progerinin is a drug that has been shown to be effective against premature aging, and is a BCS class II molecule that exhibits high apparent permeability and low solubility in aqueous media according to the Biopharmaceutical Classification System (BCS) criteria.

[0009] The therapeutic application of progerinin drugs is very limited due to their low water solubility characteristics. To overcome these limitations, numerous methods have been investigated, such as the use of polymeric nanoparticles, solid lipid nanoparticles, self-emulsifying drug delivery systems, nanoemulsions, liposomes, nanosuspensions, and nanofibers. Among them, nanosuspensions refer to colloidal dispersions of drug particles stabilized under conditions of either polymers, surfactants, or both. Nanosuspensions are used to deliver drug substances that exhibit low water solubility and lipid solubility. The small particles of nanosuspensions provide a very large drug surface area, increasing the dissolution rate of insoluble drugs. As a result, BCS class II and IV compounds exhibit improved bioavailability, fast activity, and other desirable biopharmaceutical effects.

[0010] Under such circumstances, the present inventors have realized that although animal experiments could be conducted using a mixture of monoolein and tricaprin, which is an oil-based solution, it is not possible to use a dosage form dissolved in oil when high doses and long-term administration are required due to the characteristics of the disease, and that it is necessary to develop a new dosage form that can be administered for a long period of time. In particular, the above-mentioned progerinin is so poorly soluble in water that its solubility is close to zero, and it also has very low solubility in existing ingestible solvents, so that it is necessary to develop a dosage form that can be administered for a long period of time and absorbed by the human body through the introduction of new technology.

[0011] Therefore, the present inventors have attempted to develop a nanosuspension formulation suitable for a progerinin drug having a preventive or therapeutic effect on premature aging and a method for manufacturing the same. Specifically, the inventors have attempted to develop an oral progerinin nanosuspension formulation containing a progerinin drug with improved stability, excellent dispersibility or uniformity, and improved bioavailability by optimizing the particle size of the progerinin drug with excellent bioabsorption efficiency and selecting water-soluble polymers, excipients, etc. for the manufacture of the nanosuspension. Summary of the Invention [Problem to be solved by the invention]

[0012] The object of the present invention is to provide a method for preparing a nanosuspension containing a progerinin drug with excellent bioavailability. Another object of the present invention is to provide a dosage form that is easy to take orally and has improved stability as well as bioavailability of the drug. [Means for solving the problem]

[0013] In order to achieve the above object, the present invention provides a nanosuspension containing progerinin, which comprises: (a) 1 to 10 wt% of a progerinin compound represented by the following chemical formula 1; (b) 0.5 to 5 wt% of hydroxypropyl methylcellulose (HPMC) as a polymeric suspending agent; (c) 0.5 to 5 wt% of D-α-tocopherol polyethylene glycol succinate (TPGS) as a solubility enhancer; and (d) 0.1 to 0.5 wt% of potassium sorbate as a preservative, wherein the progerinin compound is in the form of drug particles formed by wet type ball milling to have an average particle size (D50) of 100 to 300 nm.

[0014] In order to achieve the other object, the present invention provides a progerinin-containing nanosuspension comprising: (a) 1 to 10 wt % of a progerinin compound represented by the following chemical formula 1; (b') 0.5 to 5 wt % of a polymeric suspending agent, hydroxypropyl cellulose (HPC); (c') 0.1 to 0.5 wt % of a surfactant, dioctyl sodium succinate (DOSS); and (d) 0.1 to 0.5 wt % of a preservative, potassium sorbate; wherein the progerinin compound is drug particles formed by wet ball milling to have an average particle size (D50) of 100 to 300 nm.

[0015] In order to achieve the above-mentioned further object, the present invention provides a method for producing a nanosuspension containing progerinin, comprising the steps of: (i) mixing hydroxypropyl methylcellulose (HPMC) (b) and D-α-tocopherol polyethylene glycol succinate (TPGS) (c) with purified water to prepare a vehicle solution, and then adding and mixing progerinin (a) represented by the following chemical formula 1 to prepare a suspension; (ii) subjecting the suspension to wet ball milling to prepare a nanosuspension; and (iii) mixing potassium sorbate (d) with the nanosuspension to finally prepare a nanosuspension having improved stability; wherein the progerinin compound in the nanosuspension in step (iii) is in the form of drug particles having an average particle size (D50) of 100 to 300 nm.

[0016] In order to achieve the above-mentioned further object, the present invention provides a method for preparing a nanosuspension containing progerinin, comprising the steps of: (i) mixing hydroxypropyl cellulose (HPC) (b') and dioctyl sodium succinate (DOSS) (c') in purified water to prepare a vehicle solution, and then adding and mixing progerinin (a) represented by the following chemical formula 1 to prepare a suspension; (ii) subjecting the suspension to wet ball milling to prepare a nanosuspension; and (iii) mixing potassium sorbate (d) with the nanosuspension to finally prepare a nanosuspension having improved stability; wherein the progerinin compound in the nanosuspension in step (iii) is in the form of drug particles having an average particle size (D50) of 100 to 300 nm.

[0017] [ka] Effect of the Invention

[0018] The present invention relates to a nanosuspension formulation suitable for poorly soluble progerinin drugs and a method for preparing the same. The nanosuspension according to the present invention is prepared by mixing a micronized progerinin drug with a water-soluble polymer such as hydroxypropylmethylcellulose (HPMC) or hydroxypropylcellulose (HPC); a dissolution enhancer such as D-α-tocopherol polyethylene glycol succinate (TPGS) or a surfactant such as dioctyl sodium succinate (DOSS); and a preservative such as potassium sorbate, and ball milling the mixture in a Dyno-Mill chamber for a predetermined period of time. In the case of a nanosuspension containing drug particles having an average particle size of 200 nm or less, the nanosuspension showed excellent bioavailability (Example 1-1 and FIG. 1).

[0019] As described above, the nanosuspension containing progerinin as an active ingredient according to the present invention has uniform dispersibility and stability, and experimental results confirmed that the nanosuspension maintains particle uniformity of 200 nm or less for more than 20 days (up to about 70 days) at 4°C, demonstrating excellent dispersion stability and excellent bioabsorption efficiency. [Brief description of the drawings]

[0020] [Figure 1] 1 shows the pharmacokinetic analysis results of progerinin suspension. [Diagram 2] 1 shows the results of measuring the solubility of solid dispersions produced using hot melt extrusion (HMT). [Diagram 3] 1 shows the results of measuring the solubility of solid dispersions prepared using a hot melt extrusion process with polymers at various ratios (1:1). [Figure 4]Pharmacokinetic analysis results for solid dispersions prepared using a hot melt extrusion process. [Diagram 5] The results are the solubility measurements for amorphous solid dispersions using the spray drying process (A: pH 1.2, B: pH 6.8). [Figure 6] Pharmacokinetic analysis results for solid dispersions prepared using a spray drying process. [Figure 7] The shape of the nanosuspension prepared by wet ball milling using beads (top) and the results of measuring the average particle size of the progerinin drug (bottom). [Figure 8] 1 is a diagram showing a process for preparing a nanosuspension according to the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0021] The present invention will now be described in more detail.

[0022] The inventors have completed a method for producing a progerinin nanosuspension in which micronized progerinin drug is mixed with a vehicle solution containing hydroxypropyl methylcellulose (HPMC), D-α-tocopherol polyethylene glycol succinate (TPGS) and potassium sorbate, and then wet ball milled in a Dyno-Mill chamber for a specified period of time to obtain a nanosuspension, which contains particles with an average particle size (D50) of 200 nm or less, has uniform particle dispersion, and maintains its dispersion for more than 20 days at 4°C, making it stable and improving its bioavailability.

[0023] Thus, the present invention provides nanosuspensions comprising progerinin with improved bioavailability.

[0024] Specifically, as one example, the nanosuspension according to the present invention contains (a) 1 to 10 wt % of a progerinin compound represented by the following chemical formula 1; (b) 0.5 to 5 wt % of hydroxypropyl methylcellulose (HPMC) as a polymeric suspending agent; (c) 0.5 to 5 wt % of D-α-tocopherol polyethylene glycol succinate (TPGS) as a solubility enhancer; and (d) 0.1 to 0.5 wt % of potassium sorbate as a preservative.

[0025] In another embodiment, the nanosuspension according to the present invention comprises: (a) 1 to 10% by weight of a progerinin compound represented by the following chemical formula 1; (b') 0.5 to 5% by weight of a polymeric suspending agent, hydroxypropyl cellulose (HPC); (c') 0.1 to 0.5% by weight of a surfactant, dioctyl sodium succinate (DOSS); and (d) 0.1 to 0.5% by weight of a preservative, potassium sorbate.

[0026] [ka]

[0027] The progerinin (a) is a decursin derivative, and is (7S)-(+)-8,8-dimethyl-7-(3-phenyl-allyloxy)-7,8-dihydro-6H-pyrano[3,2-g]chromen-2-one. In the present invention, progerinin can also be named "SLC-D011".

[0028] The progerinin drug shows excellent progerin expression inhibitory effects and progerin and lamin A binding inhibitory effects, and has the effect of extending the survival time of an animal model in which progerinism is induced, and is used as a pharmaceutical composition for preventing or treating progerinism, an age-related disease. Progerinin is poorly soluble in water, with a solubility close to 0, but the present invention provides a dosage form that improves the solubility and allows long-term administration and absorption by the human body.

[0029] Specifically, in the present invention, hydroxypropylmethylcellulose (HPMC) (b) or hydroxypropylcellulose (HPC) (b'), which corresponds to a water-soluble polymer that is a polymer suspending agent, is a component that helps disperse the progerinin drug and other components in the solution. The polymer suspending agent is preferably included in an amount of 0.5 to 5% by weight based on the total weight of the nanosuspension, and more preferably 1 to 3% by weight.

[0030] If the polymer suspending agent is contained below the range, the settling rate of the suspension becomes poor, and if the polymer suspending agent is contained above the range, stirring becomes difficult, making manufacturing difficult. In particular, if the polymer suspending agent is contained above the range, stirring is not uniform and the dispersibility of the suspension decreases, which causes a problem of an increase in the amount of defective products that do not reach the required content during production.

[0031] In the present invention, the solubility enhancer D-α-tocopherol polyethylene glycol succinate (TPGS) (c) is a component that improves the solubility of poorly soluble drugs. The TPGS is preferably contained in an amount of 0.5 to 5% by weight based on the total weight of the nanosuspension. More preferably, it is contained in an amount of 1% by weight. If the solubility enhancer is contained below this range, the solubility will be low, and if the solubility enhancer is contained above this range, the acceptable toxicity limit may be exceeded. Therefore, it is preferable to use the solubility enhancer within the above range.

[0032] In addition, in the present invention, a surfactant, dioctyl sodium succinate (DOSS) (c'), can be used instead of the solubility enhancer. In this case, the surfactant is preferably used in an amount of 0.1 to 0.5% by weight. More preferably, it is 0.25% by weight. If the surfactant is contained below this range, the solubility is reduced, and if the surfactant is contained above this range, the acceptable toxicity limit may be exceeded, so it is preferable to use the surfactant within this range.

[0033] The poorly soluble drug progerinin in the suspension preferably has an average particle size (D50) of 100-300 nm. More preferably, the average particle size is 150-250 nm, and even more preferably, the average particle size is 200 nm or less. When the average particle size is within the above range, the solubility is excellent, and the nanoparticles have a larger surface area and are more easily dissolved, so that the bioavailability or bioabsorption efficiency can be maximized. This was confirmed through Example <1-1> described later. In addition, a nanosuspension having the above average particle size can be prepared by wet ball milling using a Dyno Mill.

[0034] In the present invention, "stability" may include any of homogeneity, dispersibility, precipitation stability, and storage stability of drug particles. In particular, the nanosuspension according to the present invention has a uniform dispersibility for 20 days or more at 4°C, and has an advanced effect in terms of improving the ease of manufacture and storage stability of the suspension.

[0035] Meanwhile, "sinking rate" refers to the speed and degree of sinking of particles in a fluid, and in the case of a suspension, in order to be approved for sale as a drug, it must satisfy a certain level of sinking rate (0.9 or more is required, where 1 is the maximum). The nanosuspension according to the present invention has the advantage of having a very excellent sinking rate by using a vehicle solution containing hydroxypropyl methylcellulose (HPMC), TPGS or dioctyl sodium succinate (DOSS), and potassium sorbate, which are suitable for progerinin drugs.

[0036] The pH of the suspension of the present invention is 5.5 to 8.5, and preferably 6.0 to 7.0.

[0037] The nanosuspension has a viscosity of 2 to 8.5 mPa·s, and preferably 7 to 8.5 mPa·s.

[0038] The nanosuspensions of the present invention may further comprise one or more ingredients selected from the group consisting of sweetening agents, preservatives, flavoring agents, pH adjusting agents and coloring agents.

[0039] The term "sweetener" as used herein refers to a food additive that provides (reproduces) sweetness but generally has a lower food calorie content, and includes both natural and synthetic sweeteners. The sweetener may be any sweetener commonly used in the food and pharmaceutical fields and may be applied to the present invention without limitation.

[0040] The term "preservative" as used in the present invention means a pharma- ceutically acceptable substance that prevents decomposition due to microbial growth or undesired chemical changes. The preservative has bactericidal and / or fungicidal or antioxidant properties, and in the present invention, potassium sorbate (d) is preferably used at 0.1-0.5 wt%, more preferably 0.2 wt%. Within the above range, the shelf life can be improved without impairing the efficacy of the drug. When added before milling, the content decreases, so it is preferable to add it after milling to complete the nanosuspension.

[0041] The term "flavor, flavor, flavor" or "aroma" as used herein includes flavoring ingredients or compositions commonly used in the food industry, whether of natural or synthetic origin, including single compounds or mixtures.

[0042] The term "pH adjusting agent" as used in the present invention refers to an excipient used to adjust the pH of the suspension to a desired value, such as, but not limited to, citric acid, sodium citrate, or ascorbic acid, and any agent commonly used in the technical field of the present invention may be used in the present invention without limitation.

[0043] The term "colorant" as used in the present invention refers to a colorant that is included to change the color of the suspension, and can be used to prepare a suspension having a desired color by being included in a dosage form. Any colorant commonly used in the technical field of the present invention is included in the present invention without any limitations.

[0044] The present invention also provides a method for preparing a nanosuspension containing a poorly soluble decurcin derivative drug with improved bioavailability and stability.

[0045] Specifically, as one embodiment, the method for producing a nanosuspension according to the present invention includes the steps of: (i) mixing hydroxypropyl methylcellulose (HPMC) (b) and D-α-tocopherol polyethylene glycol succinate (TPGS) (c) with purified water to prepare a vehicle solution, and then adding progerinin (a) represented by the following chemical formula 1 and mixing to prepare a suspension; (ii) wet ball milling the suspension to prepare a nanosuspension; and (iii) mixing potassium sorbate (d) with the nanosuspension to finally prepare a nanosuspension with improved stability.

[0046] In another embodiment, the method for preparing a nanosuspension according to the present invention includes the steps of: (i) mixing hydroxypropyl cellulose (HPC) (b') and dioctyl sodium succinate (DOSS) (c') with purified water to prepare a vehicle solution, and then adding progerinin (a) represented by the following chemical formula 1 and mixing to prepare a suspension; (ii) wet ball milling the suspension to prepare a nanosuspension; and (iii) mixing potassium sorbate (d) with the nanosuspension to finally prepare a nanosuspension having improved stability.

[0047] [ka]

[0048] The role of each component and the amount used are the same as those described above, so additional explanations will be omitted. Figure 8 is a flow chart showing a method for preparing a nanosuspension containing a poorly soluble decurcin derivative drug with improved bioavailability and stability according to the present invention.

[0049] First, in the present invention, the step (i) is a process of mixing the micronized progerinin drug with a vehicle solution, specifically, a step of mixing the polymeric suspending agent hydroxypropyl methylcellulose (HPMC) or hydroxypropyl cellulose (HPC) (b') and D-α-tocopherol polyethylene glycol succinate (TPGS) (c) or dioctyl sodium succinate (DOSS) (c') with purified water. In this case, the purified water may have a temperature of 50 to 70°C, and preferably has a temperature of 60°C. The coarse suspension thus mixed is cooled to room temperature, and then the next step is carried out to prepare a nanosuspension.

[0050] Next, in step (ii), the suspension of step (i) is subjected to wet ball milling to prepare a nanosuspension. Here, a Dyno-Mill can be used for the wet ball milling. The ball milling is preferably performed until the average particle size of the drug particles reaches 100-300 nm. More preferably, the average particle size is 150-250 nm, and even more preferably, the average particle size is 200 nm. When the average particle size is within the above range, the solubility is the highest, and the bioavailability or bioabsorption efficiency of the drug can be maximized.

[0051] In the present invention, ball milling is wet ball milling for the preparation of nanosuspension, which is a key step in the preparation of progerinin nanosuspension. Selection of suitable bead size, milling media and API ratio in the chamber, temperature control of the mill chamber, etc. are considered to be important.

[0052] Specifically, when preparing the nanosuspension, wet ball milling can be performed using the suspension of step (i) and zirconia beads having an average particle size of 0.1-1 mm, preferably 0.02-0.04 mm. The suspension of step (i) and zirconia beads can be used in a volume ratio of 1:1-1:5, but this can be appropriately changed according to the conditions as long as the average particle size (D50) of the drug can be manufactured to be 200 nm or less.

[0053] Then, in step (iii), potassium sorbate is added to the nanosuspension prepared in step (ii) to finally prepare a nanosuspension having improved stability. The addition of potassium sorbate completely disperses drug particles, thereby further improving the stability of the nanosuspension.

[0054] Meanwhile, all of the above processes include a process of mixing the poorly soluble drug with a solvent, a water-soluble polymer or a surfactant, and in this case, the nanosuspension can be prepared at a mixing speed of 500 to 1,000 rpm.

[0055] The present invention will be described in detail below with reference to examples to help the understanding of the present invention. However, the following examples are provided to more completely explain the present invention to those skilled in the art and to illustrate the contents of the present invention, and the scope of the present invention is not limited to the following examples.

[0056] Example 1: Preparation and limitations of lipid-based progerinin solution In order to overcome the poor bioavailability of the progerinin drug, the present inventors have prepared a progerinin solution using a lipid-based formulation (monoolein:tricaprylin=2:1) ​​in preclinical studies. However, lipid-based formulations were deemed unsuitable for use in a clinical setting due to inadequate drug loading and the high lipid intake expected with the proposed clinical dose. Limited attempts to produce amorphous solid dispersions (ASDs) have shown that ASDs suffer from rapid crystallization when dispersed in aqueous media. Such lipid-based formulations are also deemed unsuitable for use in a clinical setting due to inadequate drug loading and the high lipid intake expected with the proposed clinical dose.

[0057] Therefore, the present inventors intend to prepare a nanosuspension of progerinin, a poorly soluble drug, and to realize a nanosuspension optimized for clinical use by selecting a vehicle composition that improves the stability of the drug.

[0058] The manufacturing process of nanosuspension is thermodynamically unstable. Therefore, stabilizers such as polymers and surfactants are essential to maintain a physically stable state. Among the polymers, HPMC or HPC can occupy adsorption sites by fixing to the surface of drug particles, preventing drug molecules from being bound in the crystal lattice in the solution, and provide a mechanical barrier to crystallization. However, if the polymer concentration is insufficient, the crystals will grow and aggregate rapidly. If the polymer concentration continues to increase, the size of the particles will increase together due to the thick layer on the particle surface, and the diffusion between the solvent and the semi-solvent will be suppressed during the aggregation process. And as the polymer concentration increases, the osmotic pressure increases, resulting in an increase in the attractive force between colloidal particles. This leads to particle growth. Meanwhile, surfactants are adsorbed at the solid-liquid interface, reducing the surface tension at the interface and increasing the rate of nucleation, which leads to an initial decrease in particle size. Moreover, the adsorption of surfactants reduces hydrophobic interactions and coagulation, making the resveratrol particles insufficiently hydrophobic, and reducing particle growth. In particular, when SLS, an ionic surfactant, is adsorbed onto the particle surface, the particle surface becomes negatively charged. This increases the repulsive force between particles and increases the energy barrier, thereby preventing particle growth and aggregation. As a result, the addition of an appropriate concentration of a stabilizing agent can reduce the excessively high surface energy of the nanoparticles produced. In addition, the size of drug particles in the nanosuspension is an important factor in determining the bioabsorption efficiency.

[0059] Therefore, the inventors determined that the selection of stabilizers such as polymers and surfactants, and the particle size in the suspension are important factors in the preparation of a poorly soluble drug nanosuspension. First, since the size of drug particles in a drug is an important factor in determining bioabsorption efficiency, the average particle size of progerinin (SLC-D011), a drug with excellent bioabsorption efficiency, was selected, and the polymers, surfactants, preservatives, etc. for the preparation of the nanosuspension were optimized.

[0060] <1-1> Determination of the average particle size (D50) of progerinin drug As mentioned above, the size of drug particles in a drug is an important factor in determining the bioabsorption efficiency. Therefore, the present inventors analyzed the pharmacokinetics (PK) of the compound using mice in order to design a diameter size that allows smooth bioabsorption of the progerinin drug. Specifically, a microsuspension (D50=1.5mm) containing micro-sized progerinin, a nanosuspension 1 (Nano suspension 1=200nm (D=50)) containing nano-sized progerinin, and a nanosuspension 2 (Nano suspension 2=350nm (D=50)) were prepared. In this case, the microsuspension was prepared using Vivapur power, and the two nanosuspensions were prepared using zirconia beads. The suspensions thus prepared were orally administered to mice at 10mg / kg, 30mg / kg, and 100mg / kg, and the pharmacokinetics (PK) of the suspensions in vivo was analyzed to confirm the results (Figure 1).

[0061] As shown in Figure 1, it was determined that the drug would be absorbed smoothly in the body if the average particle size was 200 nm or less. Therefore, the present inventors decided to develop a suspension formulation containing drug nanoparticles with an average particle size of 200 nm or less.

[0062] In order to devise a manufacturing method that can meet such a dosage form, the inventors carried out a hot melt extrusion process, a spray drying process, a process using an ultra-high pressure homogenizer, and a process using wet ball milling with beads, and tried to select the most suitable manufacturing method for progerinin nanosuspension from among these.

[0063] <1-2> Manufacturing of amorphous solid dispersions using hot melt extrusion (HME) process First, solid dispersions were prepared for various polymers (HPMCAS, HPC, HPMC, PVP VA64, Eudragit EPO, AEA) using hot melt extrusion. In this case, a mixture was prepared with a drug to polymer ratio of 1:3. The solubility of the solid dispersions corresponding to 100 mg of progerinin was tested using 300 mL of pH 1.2 buffer (Eudragit EPO, AEA) or 300 mL of pH 6.8 buffer (HPMCAS, HPC, HPMC, PVP VA64) as the dissolution medium (Figures 2 to 4). The dissolution conditions were as follows: paddle method, temperature: 37°C, rotation speed: 150 rpm.

[0064] As shown in Figure 2, it was confirmed that the solubility was most improved when HPMCAS was used as the polymer.

[0065] Next, the HPMCAS with the highest solubility was reselected and solid dispersions were prepared in various ratios (1:2, 1:2.5, 1:3, 1:4). A solubility test was carried out for the solid dispersion equivalent to 100 mg of progerinin using 300 mL of pH 6.8 buffer as the eluent (Figure 3). The elution conditions were as follows: paddle method, temperature: 37°C, rotation speed: 150 rpm.

[0066] As shown in Figure 3, it was confirmed that the solubility is highest when the ratio of drug to HPMCAS is 1:3. However, it was confirmed that the HME method actually produced a light yellow powder form, and the solid form remained amorphous. As shown in Figure 4, the powder obtained using the HME method immediately precipitated when mixed with water, and when bioabsorption was confirmed using mice, there was almost no absorption in the body when orally administered.

[0067] Therefore, it was concluded that it is currently impossible to develop a dosage form of progerinin, the main component of the drug, using the hot melt extrusion process.

[0068] <1-3> Manufacturing of amorphous solid dispersions using the spray drying process Using the polymer of Example <1-2>, amorphous solid dispersions were prepared using a spray drying process. Solid dispersions for various polymers (HPMCAS, HPC, HPMC, PVP VA64, Eudragit EPO, AEA) were prepared using a spray drying process. In this case, a mixture was prepared with a drug to polymer ratio of 1:3. A solubility test was performed for the solid dispersions corresponding to 100 mg of progerinin using 300 mL of pH 1.2 buffer (Eudragit EPO, AEA) and 300 mL of pH 6.8 buffer (HPMCAS, HPC, HPMC, PVP VA64) as eluents (Figure 5). The elution conditions were as follows: paddle method, temperature: 37°C, rotation speed: 150 rpm.

[0069] As shown in FIG. 5, when HPMCAS was used as the polymer, as in the solid dispersion prepared by the hot melt extrusion process, the solubility of the polymer was most improved at pH 1.2 and pH 6.8.

[0070] However, when bioabsorption (PK analysis) was confirmed using mice, it was found that, similar to HME, there was almost no absorption in the body when orally administered (Figure 6). In addition, when the stability of other polymers was confirmed for two weeks under high temperature and high humidity conditions, recrystallization of progerinin particles was observed, giving unsatisfactory results (Table 1).

[0071] [Table 1]

[0072] Therefore, it was determined that it is currently impossible to develop a dosage form of progerinin, the main component of the drug, using the spray drying method.

[0073] <1-4> Manufacturing nanosuspensions using ultra-high pressure homogenizers As another method for producing nanosuspensions, the present inventors produced nanosuspensions using an ultra-high pressure homogenizer. Specifically, polymer (HPMC 3cp) and surfactant (TPGS) were dissolved in a 100 mL beaker containing distilled water, and then the drug (SLC-D011) was weighed and added, and the mixture was stirred for 2 hours to produce a suspension. The suspension was then put into an ultra-high pressure homogenizer to produce a nanosuspension (pressure: 40,000 psi, 1 hour).

[0074] [Table 2]

[0075] Table 2 shows the measurement of drug particle size, and it was confirmed that the particle size increased after 3 days. Therefore, the preparation of nanosuspension using ultra-high pressure homogenizer has the limitation that the particles become larger over time. This is also not considered to be a suitable method for preparing progerinin nanosuspension.

[0076] <1-5> Manufacturing nanosuspensions using wet ball milling with beads As another method, the present inventors prepared a nanosuspension using wet ball milling with beads. Specifically, a polymer (HPMC 3cp) and a surfactant (TPGS) were dissolved in a 100 mL beaker containing distilled water, and then progerinin was weighed and added, and the suspension was stirred for 2 hours to prepare the suspension. The tube containing the beads and the suspension was placed in a DeltaVita(R), Netzsch (Zentrimix 380R) device to prepare the nanosuspension (speed: 1200 rpm, temperature: -10°C, 6 hours). Figure 7 shows the shape (top) and the average particle size (bottom) of the nanosuspension prepared by the above method.

[0077] As shown in Figure 7, a nanosuspension containing drug nanoparticles with an average particle size of 170 nm was prepared. It was confirmed that when the average particle size of the drug particles is 200 nm or less, the stability of the nanosuspension is the most excellent in solubility, and the nanoparticles have a larger surface area and are more easily dissolved, maximizing bioavailability.

[0078] As a result, the inventors produced nanosuspensions using wet ball milling with beads, and determined that there was a need to select a vehicle composition suitable for producing nanosuspensions in which the average particle size of the drug is 200 nm or less, and attempted to select optimized polymers, surface stabilizers such as surfactants, and preservatives.

[0079] Example 2: Selection of an optimized vehicle solution <2-1> Preparation of progerinin nanosuspension a) Suspension Preparation (Step (i)) The TPGS solution is prepared by dissolving TGPS in 60°C hot water and cooling to room temperature. The HPMC E3 solution is prepared by dissolving HPMC E3 in 60°C hot water and cooling to room temperature. The two solutions are then stirred to thoroughly mix. To prepare a suspension, progerinin is gradually charged into the mixed solution as an active pharmaceutical ingredient (API) while continuing to stir.

[0080] b) Nano Milling (Step (ii)) The parameters of the Agitator Bead Mill, the mixing and wet grinding equipment, are set appropriately to begin wet ball milling, and the constant pressure pump is adjusted to circulate the suspension. The suspension exiting the Agitator Bead Mill is recirculated back to the suspension vessel while being maintained at a preset temperature of 35°C or less. The drug particles continue to undergo wet ball milling in the Dyno Mill until the PSD (D50≦200nm) is reached. Once the target PSD (D50≦200nm) is reached, the pump is turned off and the milling suspension line is separated from the suspension vessel.

[0081] c) Preparation of nanosuspensions with improved stability (step (iii)) The nanomilled suspension is mixed thoroughly with potassium sorbate as a preservative and filled into sterile glass bottles. The bottle filling process is 100% visually inspected and weight-checked, and the bottles are sealed with rubber finish and aluminum flip-off seal after filling.

[0082] <2-2> Selection of an optimized vehicle solution Progerinin nanosuspension for oral use was prepared by the method of Example <2-1>. Specifically, Prototype 1 was composed of 10.0 wt% progerinin, 3.0 wt% HPMC E3, 1.0 wt% surfactant TPGS, and 0.2 wt% potassium sorbate, and TPGS and HPMC solutions were mixed and progerinin was added to prepare a suspension. The mixture thus prepared was mixed with 0.3 mm VHD ZrO beads in a volume ratio of 1:1 to 5 and ball milled. The temperature of the container was closely monitored during the preparation process. In addition, the particle size distribution was monitored during milling until the target average particle size D50 ≦ 200 nm was reached. Prototypes 2 to 5 were also prepared in the same manner. The nanosuspension thus prepared was measured for particle diameter, zeta potential, drug content, flowability, and viscosity by the following methods.

[0083] (1) Particle diameter (D50) measurement: Approximately 2 μL of nanosuspension was dispersed in 1 mL of water, then placed in a sample tube and measured using a Zeta Potential & Particle Sizer (ZPPS) (Nicomp 380 / ZLS, Nicomp) used for aqueous suspensions. (2) Zeta potential measurement: This is a measurement of the electrical charge on the particle surface, which indicates the physical stability of the colloidal system. The zeta potential was measured using the Laser-Doppler method. (3) Drug content measurement: The content of progerinin relative to the total weight of the nanosuspension was measured. (4) Measurement of dispersibility: Dispersibility was evaluated by visual observation based on the presence or absence of precipitation in the suspension. (5) Viscosity measurement: Using a BROOKFIELD viscometer (TC-550MX-230), the torsional moment was 32.9%, the temperature was 25°C, the probe rotation speed was 200 rpm, and the viscosity was 13.03 dyne / cm 2 Shear force, 264.0 S -1 The shear rate was measured for 1 minute.

[0084] [Table 3]

[0085] From Table 3, it can be seen that the average particle size (D50) of drug particles in Prototype 1 and Prototype 3 is 165.8 nm and 146.3 nm, respectively, and both satisfy the average particle size of 200 nm or less, and the drug content is higher than 95% without detection of impurities. Therefore, it can be seen that Prototype 1 and Prototype 3 are the most suitable vehicle compositions in terms of dispersibility, stability, and drug efficacy. On the other hand, Prototype 4 had limitations in terms of drug efficacy and could not be selected as a suitable vehicle composition. Prototype 2 was not suitable as a candidate group because the particles tended to increase over time. In the case of Prototype 5, it was impossible to form a nanosuspension.

[0086] <Example 3> Preparation of suspension using roller mixer and Dyno Mill and comparison of physical properties <3-1> Manufacturing suspension using a roller mixer A roller mixer was used to prepare a nanosuspension of prototype 1 with a target concentration of 100 mg / g. Specifically, a nanosuspension of prototype 1 was prepared and mixed with zirconia beads shown in Table 2 below in a 1:1 weight ratio. The PSD was also monitored daily to observe the size reduction trend as shown in Table 4.

[0087] [Table 4]

[0088] As shown in Table 4, after 8 days of milling, the particle size is expected to remain at D90=500 nm and not decrease further. Therefore, it was concluded that it is difficult to produce a nanosuspension containing drug particles of 200 nm or less using a roller mixer.

[0089] <3-2> Production of suspension using Dyno Mill and evaluation of its physical properties Based on the results of <3-2> above, the inventors attempted to prepare a nanosuspension of prototype 1 with a target concentration of 100 mg / g using a Dyno-Mill (5 g API scale). Specifically, 45 mL of 0.5 mm zirconia beads were loaded into the Dyno-Mill milling chamber. The prepared nanosuspension of prototype 1 (5 g, 10% w / w HPMC E3, 3% / TPGS 1%) was filled into the milling chamber from the top. The machine was operated at 2,200 rpm for 5 hours with a circulating cooling liquid at -19°C. A white nanosuspension (FR00497-3-190911-100) was collected as the final nanosuspension.

[0090] In addition, a nanosuspension of 6 mg / g prototype 1 (FR00497-3-190910-6) and a nanosuspension of 20 mg / g prototype 1 (FR00497-3-190910-20) were prepared in the same manner as above. The three nanosuspensions thus collected were checked for appearance, PSD, HPLC and syringeability, and the results are shown in Table 5 below.

[0091] [Table 5]

[0092] From the results in Table 5, it was confirmed that the nanosuspension of prototype 1 satisfied all of the physical properties such as particle size and syringe passability. Additionally, the low temperature stability of the three nanosuspensions at 4°C was observed for two weeks. Specifically, the stability was evaluated by measuring the particle size to see if the average particle size (D50) was 200nm or less, and the syringe passability was evaluated by seeing if the nanosuspension could easily pass through a 20GA syringe, and the results are shown in Table 6 below.

[0093] [Table 6]

[0094] As shown in Table 6, all three nanosuspensions were stable at a low temperature of 4°C without any significant change in particle size, and were also found to have excellent syringeability. In the present invention, a mean particle size (D50) of 200 nm or less is the most ideal requirement in terms of particle dispersion stability and bioavailability of the progerinin drug.

[0095] <3-3> Manufacturing nanosuspension through scale-up In order to scale up and manufacture, the inventors tried to manufacture a nanosuspension with a target concentration of 100 mg / g using a Dyno Mill for 30 g API scale. Specifically, 45 mL of 0.3 mm zirconia beads were loaded into the Dyno Mill chamber. 30 g of the prepared progerinin was first suspended in a vehicle solution to prepare a suspension (30 g, 10% w / w in the vehicle HPMC E3 3% / TPGS 1% in water), and then the suspension was filled into the milling chamber from above. The device equipped with a circulating cooling liquid at a low temperature of -19 ° C was operated at 2,200 to 2,500 rpm for 20 hours. The PSD was monitored over time as shown in Table 7, and finally, a white nanosuspension was collected. In addition, the obtained white nanosuspension was observed for stability by observing changes in particle size for 20 to 70 days under refrigerated conditions (Table 8).

[0096] [Table 7]

[0097] From the results of Table 7, it was confirmed that progerinin drug particles having an average particle size (D50) of 200 nm or less can be successfully produced even when a nanosuspension is produced by scaling up using a Dyno Mill.

[0098] [Table 8]

[0099] As a result of Table 8, it was confirmed that the nanosuspension according to the present invention maintains stability for 20 days or more, specifically, 20 to 70 days, under refrigerated conditions.

[0100] Example 4: Selection of optimized excipients To evaluate compatibility with excipients, progerinin was mixed with HPMC E3, TPGS, and potassium sorbate in a ratio of 1:10, and the effectiveness of the API components was measured for 2 weeks at 40°C / 75% RH. The results are shown in Tables 9 and 10.

[0101] [Table 9]

[0102] [Table 10]

[0103] API:Active Pharmaceutical Ingredient(SLC-D001) From the results of Tables 9 and 10, it was confirmed that adding HPMC E3, TPGS, and potassium sorbate to the progerinin drug had no effect on the drug. In particular, in the case of preservatives, if they are added before milling, the content decreases, so it is preferable to add them after milling to complete the process. Such a study on the compatibility of pre-excipients suggests that the drug is compatible with the excipients.

[0104] <Example 5> Confirmation of stability Further stabilization studies of progerinin nanosuspension were conducted for prototype 1 and prototype 3, which showed excellent particle stability during the vehicle solution selection process. Specifically, they were evaluated for 3 weeks at 2-8°C, 40°C / RH 75%, or 1.2M lux exposure. The stabilization studies of progerinin nanosuspension were conducted at room temperature (25±5°C, 60% RH) for 3 weeks. The progerinin nanosuspension was characterized in relation to particle size and drug content. The results are shown in Tables 11 and 12.

[0105] [Table 11]

[0106] [Table 12]

[0107] From the results of Tables 11 and 12, it was confirmed that even at low temperatures or under harsh conditions, the average particle size was 200 nm or less and the nano drug particles had stability for 3 weeks or more.

[0108] Example 6: Stability of the optimized progerinin nanosuspension in simulated intestinal fluid (SIF) and simulated gastric fluid (SGF) A nanosuspension of prototype 1 was prepared using the same method as in Example <2-1>, but with the ingredients and contents in Table 13 below. The dispersion stability of the nanosuspension thus prepared in simulated intestinal fluids (SIF) and simulated gastric fluids (SGF) was confirmed. The specific experimental method is as follows.

[0109] [Table 13]

[0110] a) Simulated intestinal fluid (SIF) Monobasic potassium phosphate (6.8 gm) and sodium hydroxide (0.616 gm) were added to a 1000 mL volumetric flask with 250 mL of distilled water, swirled until the ingredients were dissolved, then an additional 700 mL of distilled water was added and the pH was measured. The pH was adjusted to pH 6.8 + / - 0.1 by adding 0.2 N sodium hydroxide or 0.2 N hydrochloric acid.

[0111] b) Simulated gastric fluid (SGF) Sodium chloride (2 gm), 750 mL of distilled water, and 7.0 mL of concentrated hydrochloric acid were added to a 1000 mL volumetric flask, followed by 1000 mL of distilled water, and the ingredients were mixed by swirling until the pH of the solution was 1.2.

[0112] c) Preparation of the dispersion An appropriate amount of prototype 1 nanosuspension was added to a translucent HDPE vial (25 mL) with an HDPE lid. It was diluted with 15 mL of simulated gastric or intestinal fluid to a final progenin concentration of 0.5 mg / mL. A dispersant was then added and the prepared dosage form was shaken until it was completely dispersed. The vial was placed in a 37°C oil bath until flocculation was observed. The size of the precipitated particles was measured using a Horiba-LA-910 particle analyzer. The material was incubated in fasted human gastric fluid for approximately 3 hours.

[0113] d) Average particle size measurement When measuring beads coated with bead cores containing insoluble particles, the weight of the bead cores was calculated in the SIF or SGF experiments and the bead cores were dispersed in the volume as SIF or SGF. 120 gm of distilled water was poured into the Horiba LA-910 chamber and then drained to make the instrument blank. Then, 120 gm of distilled water was poured and the entire volume of the incubated formulation (in 15 mL of SGF or SIF) was poured into the Horiba LA-910 chamber and the average particle size was measured.

[0114] [Table 14]

[0115] As shown in Table 14, the progenin drug (Prototype 1) with an average particle size (D50) of 200 nm or less maintained an average particle size (D50) of 190-220 nm even in simulated intestinal fluid or simulated gastric fluid, confirming that the dispersion stability and bioavailability of the drug were maintained.

[0116] Although the specific parts of the present invention have been described in detail above, it is obvious to those skilled in the art that such specific descriptions are merely preferred embodiments and do not limit the scope of the present invention. That is, the substantial scope of the present invention is defined by the claims and their equivalents.

Claims

1. (a) 1 to 10% by weight of a progerinin compound represented by the following chemical formula 1; (b) 0.5 to 5% by weight of a polymeric suspending agent, hydroxypropyl methylcellulose (HPMC); (c) 0.5-5 wt. % of the solubility enhancer D-α-tocopherol polyethylene glycol succinate (TPGS); (d) 0.1 to 0.5% by weight of potassium sorbate, which is a preservative; The progerinin compound is a drug particle formed by wet ball milling to have an average particle size (D50) of 100 to 300 nm. 【Chemistry 1】

2. (a) 1 to 10% by weight of a progerinin compound represented by the following chemical formula 1; (b') 0.5 to 5% by weight of a polymeric suspending agent, hydroxypropyl cellulose (HPC); (c') 0.1 to 0.5 wt. % of a surfactant, dioctyl sodium succinate (DOSS); (d) 0.1 to 0.5% by weight of potassium sorbate, which is a preservative; The progerinin compound is a drug particle formed by wet ball milling to have an average particle size (D50) of 100 to 300 nm. 【Chemistry 2】

3. The progerinin-containing nanosuspension according to claim 1 or 2, wherein the poorly soluble progerinin drug has an average particle size (D50) of 150-250 nm.

4. 3. The nanosuspension comprising progerinin according to claim 1 or 2, characterized in that the nanosuspension has a viscosity of 2 to 8.5 mPa·s.

5. The nanosuspension containing progerinin according to claim 1 or 2, characterized in that the nanosuspension has stability due to the uniform dispersion of drug particles for 20 days or more at a temperature condition of 4°C.

6. (i) preparing a vehicle solution by mixing hydroxypropyl methylcellulose (HPMC) (b) and D-α-tocopherol polyethylene glycol succinate (TPGS) (c) with purified water, and then adding and mixing progerinin (a) represented by the following formula 1 to prepare a suspension; (ii) wet ball milling the suspension to produce a nanosuspension; (iii) mixing potassium sorbate (d) with the nanosuspension to finally produce a nanosuspension having improved stability, The method for producing a nanosuspension containing progerinin, wherein the progerinin compound in the nanosuspension in step (iii) is in the form of drug particles having an average particle size (D50) of 100 to 300 nm. 【Chemistry 3】

7. (i) preparing a vehicle solution by mixing hydroxypropyl cellulose (HPC) (b'); and dioctyl sodium succinate (DOSS) (c'); with purified water, and then adding progerinin (a) represented by the following formula 1 and mixing to prepare a suspension; (ii) wet ball milling the suspension to produce a nanosuspension; (iii) mixing potassium sorbate (d) with the nanosuspension to finally produce a nanosuspension having improved stability, The method for producing a nanosuspension containing progerinin, wherein the progerinin compound in the nanosuspension in step (iii) is in the form of drug particles having an average particle size (D50) of 100 to 300 nm. 【Chemistry 4】

8. The method for preparing a nanosuspension containing progerinin according to claim 6 or 7, wherein the purified water in step (i) is at a temperature of 50 to 70°C.

9. The method for producing a nanosuspension containing progerinin according to claim 6 or 7, wherein in step (ii), the suspension of step (i) and zirconia beads are mixed in a volume ratio of 1:1 to 1:5 during wet ball milling, and then milled to produce a nanosuspension.

10. The method for preparing a nanosuspension containing progerinin according to claim 6 or 7, wherein the nanosuspension in step (iii) contains progerinin drug nanoparticles having an average particle size of 150 to 250 nm.

Citation Information

Patent Citations

  • Nanoparticle composition of angiogenesis inhibitor

    JP2005530712A

  • Pharmaceutical composition for preventing or treating aging-related diseases containing a decursin derivative as an active ingredient

    JP2020520895A